Literature DB >> 10602557

Costs in Perspective: Understanding Cost-Effectiveness Analysis.

.   

Abstract

This paper covers five questions: (1) What is cost-effectiveness analysis;quest; (2) How can cost-effectiveness analysis help policymakers allocate scarce resources;quest; (3) What are misconceptions about the cost effectiveness of health care interventions;quest; (4) What is an attractive cost-effectiveness ratio;quest; (5) What is the relevance of cost effectiveness to clinicians? The cost side of the equation includes more than simply the cost of the intervention, but rather the cost of all of the downstream clinical events that occur with either therapeutic alternative. Cost-effectiveness analyses are used to help decisionmakers rank programs competing for scarce resources in order to achieve the following objective: to maximize the net health benefits derived from a fixed budget for a target population. A simple example is shown. Measured cost-effectiveness ratios for selected cardiovascular interventions are displayed. The systematic use of information on effectiveness and cost effectiveness should help those involved in setting policies to have a more rational basis for funding of new programs and discontinuation of funding for old programs. In Canadian health care it is important that we use this information to make room for innovations that are effective and efficient, and to remove funding from programs that are either known to be ineffective and costly or inefficient use of resources. More energy should be put toward generating the information necessary to make these kinds of decisions.

Year:  1996        PMID: 10602557     DOI: 10.1007/BF00132409

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  9 in total

1.  Utilities and quality-adjusted life years.

Authors:  G W Torrance; D Feeny
Journal:  Int J Technol Assess Health Care       Date:  1989       Impact factor: 2.188

2.  Nonionic contrast media: economic analysis and health policy development.

Authors:  V Goel; R B Deber; A S Detsky
Journal:  CMAJ       Date:  1989-02-15       Impact factor: 8.262

Review 3.  A clinician's guide to cost-effectiveness analysis.

Authors:  A S Detsky; I G Naglie
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

4.  Five-hundred life-saving interventions and their cost-effectiveness.

Authors:  T O Tengs; M E Adams; J S Pliskin; D G Safran; J E Siegel; M C Weinstein; J D Graham
Journal:  Risk Anal       Date:  1995-06       Impact factor: 4.000

Review 5.  Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.

Authors:  C D Naylor; S Bronskill; V Goel
Journal:  Can J Cardiol       Date:  1993 Jul-Aug       Impact factor: 5.223

6.  Tentative guidelines for using clinical and economic evaluations revisited.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

7.  Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease.

Authors:  A L Hillman; B S Bloom; A M Fendrick; J S Schwartz
Journal:  Arch Intern Med       Date:  1992-07

8.  Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.

Authors:  M Krahn; A S Detsky
Journal:  Med Decis Making       Date:  1993 Jan-Mar       Impact factor: 2.583

9.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.